Search

Your search keyword '"Bonanni, Fabrizio"' showing total 12 results
Start Over Author "Bonanni, Fabrizio"
12 results on '"Bonanni, Fabrizio"'

2. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide

Author

Gurnari, Carmelo, Piciocchi, Alfonso, Soddu, Stefano, Bonanni, Fabrizio, Scalzulli, Emilia, Niscola, Pasquale, Di Veroli, Ambra, Piccioni, Anna Lina, Piedimonte, Monica, Maiorana, Gianluca, Salutari, Prassede, Cicconi, Laura, Santopietro, Michelina, Gumenyuk, Svitlana, Sarlo, Chiara, Fenu, Susanna, Tafuri, Agostino, Latagliata, Roberto, Fianchi, Luana, Criscuolo, Marianna, Maciejewski, Jaroslaw P., Maurillo, Luca, Buccisano, Francesco, Breccia, Massimo, and Voso, Maria Teresa

Published
2022
Full Text
View/download PDF

3. Fatal acute graft-versus-host disease in Sezary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation

Author

Trotta, Gentiana Elena, primary, Ciangola, Giulia, additional, Cerroni, Ilaria, additional, Mezzanotte, Valeria, additional, Nunzi, Andrea, additional, Anemona, Lucia, additional, Savino, Luca, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Bonanni, Fabrizio, additional, Meddi, Elisa, additional, Zizzari, Annagiulia, additional, Rapisarda, Vito Mario, additional, Mangione, Ilaria, additional, Bruno, Antonio, additional, Cantonetti, Maria, additional, Venditti, Adriano, additional, and Cerretti, Raffaella, additional

Published
2024
Full Text
View/download PDF

4. OVERLAPPING FEATURES OF HEPATIC COMPLICATIONS AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN A RARE T-CELL LYMPHOMA: A CLINICAL CHALLENGE

Author

Nunzi, Andrea, primary, Ciangola, Giulia, additional, Cerroni, Ilaria, additional, Mezzanotte, Valeria, additional, Trotta, Gentiana Elena, additional, Meconi, Federico, additional, Zizzari, Annagiulia, additional, Rapisarda, Vito Mario, additional, Savino, Luca, additional, Brega, Arianna, additional, Argirò, Renato, additional, De Angelis, Gottardo, additional, Mariotti, Benedetta, additional, Bonanni, Fabrizio, additional, Meddi, Elisa, additional, Gurnari, Carmelo, additional, Bruno, Antoine, additional, Mangione, Ilaria, additional, Venditti, Adriano, additional, and Cerretti, Raffaella, additional

Published
2023
Full Text
View/download PDF

5. Overlapping features of hepatic complications after hematopoietic cell transplantation in a rare T-cell lymphoma: A clinical challenge

Author

Nunzi, Andrea, Ciangola, Giulia, Cerroni, Ilaria, Mezzanotte, Valeria, Trotta, Gentiana Elena, Meconi, Federico, Zizzari, Annagiulia, Rapisarda, Vito Mario, Savino, Luca, Brega, Arianna, Argirò, Renato, De Angelis, Gottardo, Mariotti, Benedetta, Bonanni, Fabrizio, Meddi, Elisa, Gurnari, Carmelo, Bruno, Antoine, Mangione, Ilaria, Venditti, Adriano, and Cerretti, Raffaella

Published
2024
Full Text
View/download PDF

6. Acute leukemia diagnosis during the COVID-19 pandemic

Author

GUARNERA, Luca, primary, BUZZATTI, Elisa, additional, MARCHESI, Francesco, additional, ARMIENTO, Daniele, additional, MAZZONE, Carla, additional, CAPRIA, Saveria, additional, SCALZULLI, Emilia, additional, MALFONA, Francesco, additional, CHIARETTI, Sabina, additional, PALMIERI, Raffaele, additional, PATERNO, Giovangiacinto, additional, FRANZESE, Chiara, additional, BONANNI, Fabrizio, additional, SAVI, Arianna, additional, PASQUALONE, Gianmario, additional, MORETTI, Federico, additional, MAURILLO, Luca, additional, BUCCISANO, Francesco, additional, VENDITTI, Adriano, additional, and DEL PRINCIPE, Maria Ilaria, additional

Published
2023
Full Text
View/download PDF

7. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Author

Molica, Matteo, primary, Mazzone, Carla, additional, Niscola, Pasquale, additional, Carmosino, Ida, additional, Di Veroli, Ambra, additional, De Gregoris, Cinzia, additional, Bonanni, Fabrizio, additional, Perrone, Salvatore, additional, Cenfra, Natalia, additional, Fianchi, Luana, additional, Piccioni, Anna Lina, additional, Spadea, Antonio, additional, Luzi, Giovanni, additional, Mengarelli, Andrea, additional, Cudillo, Laura, additional, Maurillo, Luca, additional, Pagano, Livio, additional, Breccia, Massimo, additional, Rigacci, Luigi, additional, and De Fabritiis, Paolo, additional

Published
2022
Full Text
View/download PDF

8. Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Author

Molica, Matteo, Mazzone, Carla, Niscola, Pasquale, Carmosino, Ida, Di Veroli, Ambra, De Gregoris, Cinzia, Bonanni, Fabrizio, Perrone, Salvatore, Cenfra, Natalia, Fianchi, Luana, Piccioni, Anna Lina, Spadea, Antonio, Luzi, Giovanni, Mengarelli, Andrea, Cudillo, Laura, Maurillo, Luca, Pagano, Livio, Breccia, Massimo, Rigacci, Luigi, De Fabritiis, Paolo, Pagano, Livio (ORCID:0000-0001-8287-928X), Molica, Matteo, Mazzone, Carla, Niscola, Pasquale, Carmosino, Ida, Di Veroli, Ambra, De Gregoris, Cinzia, Bonanni, Fabrizio, Perrone, Salvatore, Cenfra, Natalia, Fianchi, Luana, Piccioni, Anna Lina, Spadea, Antonio, Luzi, Giovanni, Mengarelli, Andrea, Cudillo, Laura, Maurillo, Luca, Pagano, Livio, Breccia, Massimo, Rigacci, Luigi, De Fabritiis, Paolo, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Simple Summary Intensive induction strategies are rarely used for older patients in community on-cology practice, with comorbidities being the major cause of contraindication. We conducted a multicentric retrospective study to evaluate activity and safety in a real-life setting of hypomethylating drugs (HMAs) in patients older than 75 years with AML. In multivariate analysis, age (>= 80), Charlson comorbidity index (>= 3), creatinine clearance and the type of best response (>= PR) during treatment maintained independent significance in predicting survival. Furthermore, our data show that HMAs have similar efficacy compared to pivotal trials and are well tolerated in a setting of very elderly patients with several co-comorbidities. Elderly patients represent the most challenging and hard-to-treat patient population due to dismal characteristics of the disease, such as secondary-acute myeloid leukemia (AML), enrichment of unfavorable molecular genes (TP53) and comorbidities. We conducted a multicentric retrospective study to evaluate activity and safety in a real-life setting of hypomethylating drugs (HMAs) in patients older than 75 years with AML. Between September 2010 and December 2021, 220 patients were treated, 164 (74.5%) received AZAcitidine and 56 DECitabine; most patients (57.8%), received more than four cycles of HMAs. The best response obtained was CR in 51 patients (23.2%), PR in 23 (10.5%) and SD in 45 (20.5%); overall transfusion independence was obtained in 47 patients (34%), after a median of 3.5 months. The median OS (mOs) was 8 months (95% CI 5.9-10.2), with 1- and 2-years OS of 39.4% (95% CI 32.7-46) and 17.4% (95% CI 11.7-23.1), respectively; similar mOS was observed according to HMA treatment (AZA 8.3 vs. DEC 7.8 months, p = 0.810). A subset of 57 long survivors (44 in AZA group and 13 in DEC group) received at least 12 cycles of HMAs, their mOS was 24.3 months. In multivariate analysis, age (>= 80), Charlson comorbidity index (>= 3

Published
2022

9. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia

Author

Paterno, Giovangiacinto, primary, Guarnera, Luca, additional, Palmieri, Raffaele, additional, Del Prete, Valentina, additional, Bonanni, Fabrizio, additional, Buzzatti, Elisa, additional, Moretti, Federico, additional, Casciani, Paola, additional, Savi, Arianna, additional, Di Cave, David, additional, Maurillo, Luca, additional, Buccisano, Francesco, additional, Venditti, Adriano, additional, and Del Principe, Maria Ilaria, additional

Published
2021
Full Text
View/download PDF

10. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia.

Author

Paterno, Giovangiacinto, Guarnera, Luca, Palmieri, Raffaele, Del Prete, Valentina, Bonanni, Fabrizio, Buzzatti, Elisa, Moretti, Federico, Casciani, Paola, Savi, Arianna, Di Cave, David, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, and Del Principe, Maria Ilaria

Subjects
ACUTE myeloid leukemia, OLDER patients, SMOKING, IMMUNOCOMPROMISED patients, HIV infections, CANCER chemotherapy, PNEUMOCYSTIS pneumonia
Abstract

Background: Several studies in immunocompromised patients, such as those with HIV infection, undergoing cancer chemotherapy or organ transplant, have led to the development of guidelines on the use of prophylaxis to prevent Pneumocystis jirovecii pneumonia (PJP), in these specific conditions. Instead, since the association between PJP and acute myeloid leukaemia (AML) is not clearly defined, the role of prophylaxis in patients with AML is not yet established. Methods: We retrospectively analysed 251 consecutive patients with newly diagnosed non‐M3‐AML, admitted at the Hematology Unit of University Tor Vergata in Rome, during the period 2010–2020. The aim of the study was to evaluate the incidence of PJP among AML patients during their first hospital admission, and to identify subjects at a high risk to develop PJP. Results: Among 251 consecutive patients with non‐M3‐AML, 67 bronchoalveolar lavages (BAL) were performed. PJP was proven in 11/67 (16.7%) subjects undergoing BAL (11 males, median age 71 years), with an incidence of 4.3%. The most common reason for BAL execution were radiological findings such as ground‐glass opacities (6/11, 55%) and atypical patterns like consolidations and nodules (5/11, 45%). One patient died because of PJP after 11 days of trimethoprim/sulfamethoxazole therapy. In multivariate analysis older age and smoking habit were independent factors significantly associated with PJP (p =.021 and 0.017 respectively). Conclusion: We conclude that PJP infection is not uncommon among patients with AML. If intensive chemotherapy is planned, physicians should be aware of this risk and prophylaxis should be considered, particularly in older patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results